It is with great pleasure to announce that Swiss HLG is welcoming our new board member Monika Baudler-Klein, joining us from our valued long term supporter Roche.

Monika holds a PhD in Biochemistry from University of Würzburg and has been in the pharmaceutical industry for more than 25 years working in various discovery, development, commercial and licensing roles with a focus on people and project leadership, portfolio management and strategy giving her a true end-to-end perspective on bringing transformative medicines to patients. 

Before joining Roche in 2012, she served as Global Head of Pipeline Sourcing and Portfolio Management at Nycomed where she and her team drove an ambitious in-licensing strategy to complement the company’s portfolio. In her time in Roche, Monika initially focused on supporting the growing Neurology pipeline from a portfolio, commercial and in-licensing strategy perspective before taking on the leadership of the late stage Alzheimer’s portfolio as Life Cycle Leader Gantenerumab and Crenezumab. 

A catalyst for building trustful relationships with internal and external stakeholders, she recently joined Roche’s Corporate Business Development as Executive Director Global Alliance & Asset Management leveraging her broad experience in skillfully managing partnerships with diverse external groups and organizations. 

Monika adds: ¨I am thrilled to be joining the exceptional and highly experienced Swiss HLG Board and I look forward to making an impact on the active Swiss health care community by contributing my broad pharma expertise and by fostering productive partnerships and cross-industry collaboration.”

We are delighted to reveal that the IPLS, the umbrella organisation for all PLG/HLG groups across Europe and Canada, is launching a new IPLS Community Platform, to replace the previous IPLS database. 

This is a unique resource that will enable Swiss HLG members to reach out to fellow members, as well as members of other IPLS national groups such as the UK PLG. It is a completely private platform with exciting modern functionality, including a newsfeed and discussion forums. Access to the platform is a significant benefit of Swiss HLG membership. Together with the UK PLG, we are pioneers in adopting the new system and other groups will come on board over the summer. The official launch will be at the IPLS conference on September 16-18 in Malaga. 

We hope to celebrate the launch with you there!

Registration is now open for the ever-popular IPLS pre-CPHI networking drinks reception - take advantage of the early bird rate and register now!

Discover the Real Impact of AI in Biopharma! Join us for the 'AI Transforming BioPharma Panel: Beyond the Hype' at the hashtag#Sachs_BEF on September 25th, 2024, at the Mövenpick Hotel Basel. Explore the genuine advancements and practical applications of artificial intelligence that are revolutionizing biopharmaceuticals.

Chaired by:
Sarah Holland, President of Swiss HLG & CBO, Cureteq AG - a Partex Company
Panellists:
Frank Grams, Chief Commercial Officer, Partex N.V.
Katharina Kreymborg, SVP (CSO Partner Team), Curie.Bio
Parker Moss, EVP Corporate Development, Exscientia Ltd.
Patrick Schwab, Senior Director, AI & Machine Learning, GSK
Ricardo Gaminha Pacheco, Strategic Partnering, Business Development & Licensing Director, Insilico Medicine

This panel will cut through the noise to examine how AI technologies are truly transforming drug discovery, development, and market strategies. Engage with industry experts as they discuss overcoming challenges, achieving breakthroughs, and forecasting the future of AI in biopharma.

Don’t miss this opportunity to gain in-depth insights and network with pioneers in the field. Secure your spot today at www.sachsforum.com/24bef and join us, both hashtag#InPerson & hashtag#Online, during the Sachs Autumn Life Sciences Week.

Stay Ahead in Bio-Pharma Dealmaking! Join us for the 'Latest Trends in Dealmaking for Bio-Pharma Panel' at the hashtag#Sachs_BEF on September 26th, 2024, at the Mövenpick Hotel Basel. Discover the strategies driving successful partnerships and transactions in the biopharmaceutical sector.

Co-Chaired by:
Sandra von Meier, Head Business Development & Licensing, Debiopharm International S.A.
Sarah Holland, President of Swiss HLG & CBO, Cureteq AG - a Partex Company

Panellists:
Alessandra Polara, Senior Director, Global BD, F. Hoffmann-La Roche AG
Berthold Hinzen, Global Head BD&L Transactions Immunology, Novartis AG
Jeremy Griggs, Executive Director, Business Development, GSK
Richard Ward, Executive Director, Search & Evaluation, AstraZeneca

This panel offers a deep dive into the evolving landscape of dealmaking in the biopharma industry. Learn from top executives and dealmakers as they explore the latest trends, strategies, and challenges in mergers, acquisitions, and strategic partnerships. Gain insights into how these dynamics are shaping the industry and what it means for future innovation and growth.

Don’t miss this chance to enhance your strategic decision-making and networking capabilities. Secure your spot today at www.sachsforum.com/24bef and join us, both hashtag#inperson & hashtag#online, during the Sachs Autumn Life Sciences Week.